APA (7th ed.) Citation

X, S., J, Y., Y, D., & D, F. (2026). Adjuvant chemotherapy combined with pembrolizumab immunotherapy for primary triple-negative neuroendocrine carcinoma of the breast: A case report and literature review. Frontiers in immunology, 17, 1848635. https://doi.org/10.3389/fimmu.2026.1848635

Chicago Style (17th ed.) Citation

X, Shen, Yang J, Du Y, and Fu D. "Adjuvant Chemotherapy Combined with Pembrolizumab Immunotherapy for Primary Triple-negative Neuroendocrine Carcinoma of the Breast: A Case Report and Literature Review." Frontiers in Immunology 17 (2026): 1848635. https://doi.org/10.3389/fimmu.2026.1848635.

MLA (9th ed.) Citation

X, Shen, et al. "Adjuvant Chemotherapy Combined with Pembrolizumab Immunotherapy for Primary Triple-negative Neuroendocrine Carcinoma of the Breast: A Case Report and Literature Review." Frontiers in Immunology, vol. 17, 2026, p. 1848635, https://doi.org/10.3389/fimmu.2026.1848635.